第2屆NBRP Pitch Day傑出團隊-「開發治療性人源化CD24單株抗體應用於轉移性三陰性乳癌的精準標靶治療」

三陰性乳癌是乳癌中最容易復發和遠端轉移的亞型，由於適用的標靶藥物有限，使得其成為臨床乳癌治療的一大挑戰，因此轉移性三陰性乳癌仍是未被滿足的醫療需求。研發團隊在2019年率先提出抗CD24療法有潛力作為治療轉移性三陰性乳癌的新療法，而近年來CD24更被證實為巨噬細胞的免疫檢查點，從而開啟了新一代免疫檢查點療法新契機。我們團隊研發的治療性人源化CD24抗體HH0146，為國內人源化CD24抗體抗腫瘤專利技術的領先者，能專一性地活化巨噬細胞的優異吞噬腫瘤能力，同時也能激活自然殺手細胞以毒殺腫瘤，調節腫瘤免疫微環境，從而實現卓越的抗腫瘤效果。HH0146抗體藥已獲台灣發明專利及完成國際專利佈局申請(PCT/US24/13014:未公開)。

Triple-negative breast cancer (TNBC) is the subtype of breast cancer that is most prone to recurrence and distant metastasis. The limited availability of targeted therapies makes it a significant challenge in clinical breast cancer treatment, resulting in an unmet medical need for metastatic TNBC. In 2019, our research team was the first to propose the potential of anti-CD24 therapy as a new treatment for metastatic TNBC. Recently, CD24 has been confirmed as an immune checkpoint in macrophages, opening new opportunities for the next generation of immune checkpoint therapies. Our team has developed the therapeutic humanized anti-CD24 antibody HH0146, which is at the forefront of domestic patent technology for humanized anti-CD24 antibody targeting tumors. HH0146 can specifically activate the excellent phagocytosis of macrophages while also activating natural killer cells to kill tumors, thereby modulating the tumor immune microenvironment and achieving outstanding anti-tumor efficacy. The HH0146 antibody has obtained a Taiwanese invention patent and has completed international patent application filings (PCT/US24/13014: unpublished).

團隊成員包含王陸海及詹世萱